ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Oral Abstract Session

Breakthroughs in Anemia and Iron Management

October 22, 2020 | 05:00 PM - 07:00 PM

Location: Simulive

Session Description

Oral Abstract Session

Learning Pathway(s)

  • Bone and Mineral Metabolism


  • Steven Fishbane, MD
  • Jay B. Wish, MD, FASN


  • Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD
    05:00 PM - 07:00 PM
    Kai-Uwe Eckardt, MD 
  • Roxadustat for the Treatment of Anemia in CKD Patients Not on Dialysis (NDD): A Phase 3, Randomized, Open-Label, Active-Controlled Study
    05:00 PM - 07:00 PM
    Jonathan Barratt, MBChB, PhD 
  • Roxadustat Treatment Results in Consistent Improvements in Hemoglobin (Hb) vs. Placebo: An Analysis of Three Multinational Randomized Clinical Trials in Patients with Non-Dialysis-Dependent CKD (NDD-CKD)
    05:00 PM - 07:00 PM
    Roberto Pecoits-Filho, MD, PhD, FASN
  • Roxadustat Treatment of Anemia in Non-Dialysis-Dependent CKD Is Not Influenced by Iron Status
    05:00 PM - 07:00 PM
    Robert Provenzano, MD, FASN 
  • Roxadustat Is Not Associated with an Increased Risk of Neoplasm in Patients with CKD and Anemia
    05:00 PM - 07:00 PM
    Daniel W. Coyne, MD 
  • Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD)
    05:00 PM - 07:00 PM
    Pablo E. Pergola, MD, PhD
  • Adverse Event Rates Are Higher Post-Transfusion vs. Overall Follow-up and Independent of Background Anemia Treatment in Patients with CKD
    05:00 PM - 07:00 PM
    Robert Provenzano, MD, FASN 
  • Renoprotective Effects of Ferric Citrate in a Mouse Model of CKD
    05:00 PM - 07:00 PM
    Mark R. Hanudel, MD, MS, FASN 
  • Regional Variation of Erythropoietin-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
    05:00 PM - 07:00 PM
    Ajay K. Singh, MD 
  • A Real-World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent CKD Patients, a CKDopps Study
    05:00 PM - 07:00 PM
    Marcelo Lopes, MD, PhD, MPH